Report cover image

Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Apr 29, 2022
Length 148 Pages
SKU # GMD17181965

Description

Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Drugs In Development, 2022, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape.

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leiomyosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Leiomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 25, 19, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Leiomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leiomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leiomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leiomyosarcoma (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

148 Pages
Introduction
Global Markets Direct Report Coverage
Leiomyosarcoma – Overview
Leiomyosarcoma – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Leiomyosarcoma – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leiomyosarcoma – Companies Involved in Therapeutics Development
3SBio Inc
Actuate Therapeutics Inc
Advenchen Laboratories LLC
Agenus Inc
Alphamab Oncology
ALX Oncology Holdings Inc
Apexigen Inc
APIM Therapeutics AS
Apollomics Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
BeiGene Ltd
BioAtla Inc
BioMed Valley Discoveries Inc
Calithera Biosciences Inc
Cebiotex SL
Clovis Oncology Inc
CStone Pharmaceuticals Co Ltd
Eli Lilly and Co
ENB Therapeutics LLC
EUSA Pharma (UK) Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Immix BioPharma Inc
Immodulon Therapeutics Ltd
Incyte Corp
Karyopharm Therapeutics Inc
Kuur Therapeutics Ltd
Merck & Co Inc
Merck KGaA
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Philogen SpA
PTC Therapeutics Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Bioscience Co Ltd
Tactical Therapeutics Inc
Tempest Therapeutics Inc
Tessa Therapeutics Ltd
Viracta Therapeutics Inc
Y-mAbs Therapeutics Inc
Yooyoung Pharm Co Ltd
Leiomyosarcoma – Drug Profiles
(curcumin + doxorubicin) – Drug Profile
anlotinib hydrochloride – Drug Profile
apatinib mesylate – Drug Profile
APL-502 – Drug Profile
atezolizumab – Drug Profile
ATX-101 – Drug Profile
avelumab – Drug Profile
axitinib – Drug Profile
AZD-1390 – Drug Profile
AZD-7648 – Drug Profile
baltaleucel-T – Drug Profile
berzosertib – Drug Profile
botensilimab – Drug Profile
Cabometyx – Drug Profile
Carboxyamidotriazole Orotate – Drug Profile
CEB-01 – Drug Profile
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Epstein-Barr Virus Associated Cancers – Drug Profile
CNV-NT – Drug Profile
crenigacestat – Drug Profile
dinutuximab beta – Drug Profile
DN-1508052 – Drug Profile
durvalumab – Drug Profile
ecubectedin – Drug Profile
elraglusib – Drug Profile
ENB-003 – Drug Profile
envafolimab – Drug Profile
evorpacept – Drug Profile
fibromun – Drug Profile
fulvestrant – Drug Profile
IMM-101 – Drug Profile
itacitinib adipate – Drug Profile
lurbinectedin – Drug Profile
mecbotamab vedotin – Drug Profile
nanatinostat – Drug Profile
Nivatrotamab – Drug Profile
nivolumab – Drug Profile
nofazinlimab – Drug Profile
pamiparib – Drug Profile
pembrolizumab – Drug Profile
rucaparib camsylate – Drug Profile
sapanisertib – Drug Profile
selinexor – Drug Profile
sotigalimab – Drug Profile
SSGJ-609A – Drug Profile
tabelecleucel – Drug Profile
toripalimab – Drug Profile
TPST-1120 – Drug Profile
TT-11X – Drug Profile
TTI-621 – Drug Profile
unesbulin – Drug Profile
YYB-101 – Drug Profile
Leiomyosarcoma – Dormant Projects
Leiomyosarcoma – Discontinued Products
Leiomyosarcoma – Product Development Milestones
Featured News & Press Releases
Nov 18, 2020: PTC Therapeutics announces key regulatory designations for PTC596 to advance treatment of two rare oncology indications
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Leiomyosarcoma, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Universities/Institutes, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Companies, 2022 (Contd..2)
Table 8: Products under Development by Universities/Institutes, 2022
Table 9: Number of Products by Stage and Target, 2022
Table 10: Number of Products by Stage and Target, 2022 (Contd..1)
Table 11: Number of Products by Stage and Mechanism of Action, 2022
Table 12: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 13: Number of Products by Stage and Route of Administration, 2022
Table 14: Number of Products by Stage and Molecule Type, 2022
Table 15: Leiomyosarcoma – Pipeline by 3SBio Inc, 2022
Table 16: Leiomyosarcoma – Pipeline by Actuate Therapeutics Inc, 2022
Table 17: Leiomyosarcoma – Pipeline by Advenchen Laboratories LLC, 2022
Table 18: Leiomyosarcoma – Pipeline by Agenus Inc, 2022
Table 19: Leiomyosarcoma – Pipeline by Alphamab Oncology, 2022
Table 20: Leiomyosarcoma – Pipeline by ALX Oncology Holdings Inc, 2022
Table 21: Leiomyosarcoma – Pipeline by Apexigen Inc, 2022
Table 22: Leiomyosarcoma – Pipeline by APIM Therapeutics AS, 2022
Table 23: Leiomyosarcoma – Pipeline by Apollomics Inc, 2022
Table 24: Leiomyosarcoma – Pipeline by AstraZeneca Plc, 2022
Table 25: Leiomyosarcoma – Pipeline by Atara Biotherapeutics Inc, 2022
Table 26: Leiomyosarcoma – Pipeline by BeiGene Ltd, 2022
Table 27: Leiomyosarcoma – Pipeline by BioAtla Inc, 2022
Table 28: Leiomyosarcoma – Pipeline by BioMed Valley Discoveries Inc, 2022
Table 29: Leiomyosarcoma – Pipeline by Calithera Biosciences Inc, 2022
Table 30: Leiomyosarcoma – Pipeline by Cebiotex SL, 2022
Table 31: Leiomyosarcoma – Pipeline by Clovis Oncology Inc, 2022
Table 32: Leiomyosarcoma – Pipeline by CStone Pharmaceuticals Co Ltd, 2022
Table 33: Leiomyosarcoma – Pipeline by Eli Lilly and Co, 2022
Table 34: Leiomyosarcoma – Pipeline by ENB Therapeutics LLC, 2022
Table 35: Leiomyosarcoma – Pipeline by EUSA Pharma (UK) Ltd, 2022
Table 36: Leiomyosarcoma – Pipeline by Exelixis Inc, 2022
Table 37: Leiomyosarcoma – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Table 38: Leiomyosarcoma – Pipeline by Immix BioPharma Inc, 2022
Table 39: Leiomyosarcoma – Pipeline by Immodulon Therapeutics Ltd, 2022
Table 40: Leiomyosarcoma – Pipeline by Incyte Corp, 2022
Table 41: Leiomyosarcoma – Pipeline by Karyopharm Therapeutics Inc, 2022
Table 42: Leiomyosarcoma – Pipeline by Kuur Therapeutics Ltd, 2022
Table 43: Leiomyosarcoma – Pipeline by Merck & Co Inc, 2022
Table 44: Leiomyosarcoma – Pipeline by Merck KGaA, 2022
Table 45: Leiomyosarcoma – Pipeline by Ono Pharmaceutical Co Ltd, 2022
Table 46: Leiomyosarcoma – Pipeline by Pfizer Inc, 2022
Table 47: Leiomyosarcoma – Pipeline by Pharma Mar SA, 2022
Table 48: Leiomyosarcoma – Pipeline by Philogen SpA, 2022
Table 49: Leiomyosarcoma – Pipeline by PTC Therapeutics Inc, 2022
Table 50: Leiomyosarcoma – Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
Table 51: Leiomyosarcoma – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Table 52: Leiomyosarcoma – Pipeline by Tactical Therapeutics Inc, 2022
Table 53: Leiomyosarcoma – Pipeline by Tempest Therapeutics Inc, 2022
Table 54: Leiomyosarcoma – Pipeline by Tessa Therapeutics Ltd, 2022
Table 55: Leiomyosarcoma – Pipeline by Viracta Therapeutics Inc, 2022
Table 56: Leiomyosarcoma – Pipeline by Y-mAbs Therapeutics Inc, 2022
Table 57: Leiomyosarcoma – Pipeline by Yooyoung Pharm Co Ltd, 2022
Table 58: Leiomyosarcoma – Dormant Projects, 2022
Table 59: Leiomyosarcoma – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Leiomyosarcoma, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us